ASCO: Oreronel Fails to Boost Prostate Cancer Survival

CHICAGO (MedPage Today) -- The novel anti-androgen orteronel delayed progression in chemotherapy-naive metastatic prostate cancer refractory to standard hormone therapy, but without a survival benefit.
Source: MedPage Today Urology - Category: Urology & Nephrology Source Type: news